- Home
- Publications
- Publication Search
- Publication Details
Title
Multiple myeloma: therapeutic delivery of antibodies and aptamers
Authors
Keywords
-
Journal
Therapeutic Delivery
Volume 12, Issue 10, Pages 705-722
Publisher
Future Science Ltd
Online
2021-09-27
DOI
10.4155/tde-2021-0041
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2021) M.A. Dimopoulos et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Not only in silico drug discovery: Molecular modeling towards in silico drug delivery formulations
- (2021) Tommaso Casalini JOURNAL OF CONTROLLED RELEASE
- Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
- (2021) Philippe Moreau et al. LANCET
- Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
- (2020) Lionel Rougé et al. SCIENCE
- Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma
- (2020) Ilaria Saltarella et al. Cells
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
- (2020) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Dendrimer– and polymeric nanoparticle–aptamer bioconjugates as nonviral delivery systems: a new approach in medicine
- (2020) Serge Mignani et al. DRUG DISCOVERY TODAY
- Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
- (2020) Hyun Jung Kim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy
- (2020) Zhaoying Fu et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.
- (2020) Adam D. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma
- (2020) Hans C. Lee et al. LEUKEMIA
- In silico design and validation of high-affinity RNA aptamers targeting epithelial cellular adhesion molecule dimers
- (2020) David R. Bell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial
- (2020) Marc S Raab et al. Lancet Haematology
- Belantamab Mafodotin: First Approval
- (2020) Anthony Markham DRUGS
- Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
- (2020) Outi M. H. Salo-Ahen et al. Processes
- Decoration of Anti-CD38 on Nanoparticles Carrying a STAT3 Inhibitor Can Improve the Therapeutic Efficacy Against Myeloma
- (2019) Yung-Hsing Huang et al. Cancers
- Single-Chain Variable Fragment-based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow
- (2019) Raoufeh Ahamadi-Fesharaki et al. Molecular Therapy-Oncolytics
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma
- (2019) A. Keith Stewart et al. Blood Cancer Journal
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab in High-risk Smoldering Multiple Myeloma
- (2019) Timothy A Brighton et al. CLINICAL CANCER RESEARCH
- The phase I clinical study of CART targeting BCMA with humanized alpaca-derived single-domain antibody as antigen recognition domain.
- (2019) Lu Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells
- (2019) Maria C. Ochoa et al. OncoImmunology
- Protein interactions with negatively charged inorganic surfaces
- (2019) Karina Kubiak-Ossowska et al. CURRENT OPINION IN COLLOID & INTERFACE SCIENCE
- Trial re-investment to build better research for better impact
- (2019) Thomas A Fox et al. LANCET
- Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200
- (2019) Daruka Mahadevan et al. Journal for ImmunoTherapy of Cancer
- Computational approaches to therapeutic antibody design: established methods and emerging trends
- (2019) Richard A Norman et al. BRIEFINGS IN BIOINFORMATICS
- A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma
- (2019) Irene M. Ghobrial et al. CLINICAL CANCER RESEARCH
- TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo
- (2019) Marjan Fatholahi et al. Clinical Lymphoma Myeloma & Leukemia
- HDP-101, a Novel BCMA-targeted Antibody Conjugated to α-Amanitin, is Active against Myeloma with Preferential Efficacy against Pre-clinical Models of Deletion 17p
- (2019) Ram Kumar Singh et al. Clinical Lymphoma Myeloma & Leukemia
- Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application
- (2019) Adachi et al. MOLECULES
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Both IgM and IgG Antibodies against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice
- (2019) Tien-Ching Chang et al. Pharmaceutics
- Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model
- (2018) Walhan Alshaer et al. JOURNAL OF CONTROLLED RELEASE
- Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents
- (2018) Minhee Kim et al. MOLECULES
- Nanotherapeutics for multiple myeloma
- (2018) Alexander Zheleznyak et al. Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology
- CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
- (2018) Clare Y. Slaney et al. Cancer Discovery
- A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies
- (2018) Norbert Vey et al. Oncotarget
- Pediatric Cancer Immunotherapy: Opportunities and Challenges
- (2018) Mary Frances Wedekind et al. PEDIATRIC DRUGS
- Dopamine D3 receptor antagonist reveals a cryptic pocket in aminergic GPCRs
- (2018) Noelia Ferruz et al. Scientific Reports
- Induction of multiple myeloma cancer stem cell apoptosis using conjugated anti-ABCG2 antibody with epirubicin-loaded microbubbles
- (2018) Fangfang Shi et al. Stem Cell Research & Therapy
- Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
- (2018) Yuan-Chin Hsieh et al. Theranostics
- A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma
- (2018) Wing Keung Chan et al. Cancer Immunology Research
- Aptamer Therapeutics in Cancer: Current and Future
- (2018) Yoshihiro Morita et al. Cancers
- Current Advances in Aptamers for Cancer Diagnosis and Therapy
- (2018) Shin-ichiro Hori et al. Cancers
- Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities
- (2018) Michael Stewart Pharmaceutics
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
- (2018) Sikander Ailawadhi et al. Clinical Lymphoma Myeloma & Leukemia
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Pre-clinical development of TNB-383B, a fully human T-cell engaging bispecific antibody targeting BCMA for the treatment of multiple myeloma.
- (2018) Ben Buelow et al. JOURNAL OF CLINICAL ONCOLOGY
- How dynamic docking simulations can help to tackle tough drug targets
- (2018) Maurizio Recanatini Future Medicinal Chemistry
- Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
- (2018) Graham H Jackson et al. LANCET ONCOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
- (2018) Cristina L. Abrahams et al. Oncotarget
- Aptamer Chimeras for Therapeutic Delivery: The Challenging Perspectives
- (2018) Carla Esposito et al. Genes
- Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy
- (2018) Denise Toscani et al. Frontiers in Immunology
- Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Tomas Jelinek et al. Frontiers in Immunology
- Aptamer-targeted delivery of Bcl-xL shRNA using alkyl modified PAMAM dendrimers into lung cancer cells
- (2017) Sara Ayatollahi et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Polyethylenimine-functionalized carbon nanotubes tagged with AS1411 aptamer for combination gene and drug delivery into human gastric cancer cells
- (2017) Sahar Taghavi et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study
- (2017) H Ludwig et al. LEUKEMIA
- Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma
- (2017) Matthew J. Pianko et al. LEUKEMIA & LYMPHOMA
- Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
- (2017) Thorsten Gantke et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
- (2017) Stina Wichert et al. PLoS One
- Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population
- (2016) Qi Yang et al. ANALYTICAL CHEMISTRY
- MGUS to myeloma: a mysterious gammopathy of underexplored significance
- (2016) M. V. Dhodapkar BLOOD
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma
- (2016) Noopur S. Raje et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery
- (2016) Xiaodong Xie et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy
- (2016) Zhongjian Chen et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Emerging antibodies for the treatment of multiple myeloma
- (2016) Flora Zagouri et al. EXPERT OPINION ON EMERGING DRUGS
- Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization
- (2016) Dan Chen et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer
- (2016) Thomas J. Povsic et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Pre-existing anti–polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer
- (2016) Nancy J. Ganson et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies
- (2016) Kyun Heo et al. JOURNAL OF CONTROLLED RELEASE
- Role of Molecular Dynamics and Related Methods in Drug Discovery
- (2016) Marco De Vivo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple myeloma in the very elderly patient: challenges and solutions
- (2016) Andrew J King et al. Clinical Interventions in Aging
- In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study'TIM3 Aptamers Binding
- (2016) Obdulia Rabal et al. Molecular Therapy-Nucleic Acids
- In silico selection of an aptamer to estrogen receptor alpha using computational docking employing estrogen response elements as aptamer-alike molecules
- (2016) Rajesh Ahirwar et al. Scientific Reports
- Specific aptamer-conjugated mesoporous silica–carbon nanoparticles for HER2-targeted chemo-photothermal combined therapy
- (2015) Kaiyuan Wang et al. Acta Biomaterialia
- Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma
- (2015) Jianxuan Zou et al. CANCER SCIENCE
- A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) D. M. Benson et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies and their applications
- (2015) Gaowei Fan et al. Journal of Hematology & Oncology
- An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma
- (2015) Nitya S. Ramadoss et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
- (2015) Vashti Irani et al. MOLECULAR IMMUNOLOGY
- Predicting the Uncertain Future of Aptamer-Based Diagnostics and Therapeutics
- (2015) John Bruno MOLECULES
- Anti-DNA antibodies — quintessential biomarkers of SLE
- (2015) David S. Pisetsky Nature Reviews Rheumatology
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aptamers and Their Applications in Nanomedicine
- (2015) Hongguang Sun et al. Small
- Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
- (2015) T Vu et al. Blood Cancer Journal
- Interpretation of cytogenetic results in multiple myeloma for clinical practice
- (2015) A M Rajan et al. Blood Cancer Journal
- Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model
- (2015) Cuiping Yang et al. Oncotarget
- Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models
- (2015) P. R. Rhode et al. Cancer Immunology Research
- Comparison of Drug Delivery Efficiency between Doxorubicin Intercalated in RNA Aptamer and One Encapsulated in RNA Aptamer-Conjugated Liposome
- (2015) Hanna Park et al. BULLETIN OF THE KOREAN CHEMICAL SOCIETY
- Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival
- (2015) Renji Reghunathan et al. Oncotarget
- Functional DNA-Containing Nanomaterials: Cellular Applications in Biosensing, Imaging, and Targeted Therapy
- (2014) Hao Liang et al. ACCOUNTS OF CHEMICAL RESEARCH
- Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma
- (2014) Wilson I. Gonsalves et al. Clinical Lymphoma Myeloma & Leukemia
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy
- (2014) Hongguang Sun et al. Molecular Therapy-Nucleic Acids
- Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer
- (2013) Wenjin Xu et al. BIOMATERIALS
- Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer
- (2013) Parag Parekh et al. BIOMATERIALS
- Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden
- (2013) I. Turesson et al. BLOOD
- Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma
- (2013) Jonathan L. Kaufman et al. BRITISH JOURNAL OF HAEMATOLOGY
- Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12
- (2013) A Vater et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma
- (2013) Jonathan E. Rosenberg et al. INVESTIGATIONAL NEW DRUGS
- Targeted in vitro photodynamic therapy via aptamer-labeled, porphyrin-loaded virus capsids
- (2013) Brian A. Cohen et al. JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY B-BIOLOGY
- Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial
- (2013) Bastian von Tresckow et al. LEUKEMIA & LYMPHOMA
- Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo
- (2013) Hang Xing et al. Journal of Materials Chemistry B
- The Structural Basis of Antibody-Antigen Recognition
- (2013) Inbal Sela-Culang et al. Frontiers in Immunology
- AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery
- (2012) Athulya Aravind et al. BIOTECHNOLOGY AND BIOENGINEERING
- Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
- (2012) Darrell White et al. CANCER
- Antibody-Conjugated Nanoparticles for Therapeutic Applications
- (2012) M. M. Cardoso et al. CURRENT MEDICINAL CHEMISTRY
- Extramedullary involvement in multiple myeloma
- (2012) J. Blade et al. HAEMATOLOGICA
- Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine
- (2012) Mao Ye et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Near-Infrared Light-Responsive Core–Shell Nanogels for Targeted Drug Delivery
- (2011) Huaizhi Kang et al. ACS Nano
- Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
- (2011) K. Neben et al. BLOOD
- Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
- (2011) Amrita V. Kamath et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
- (2011) F. Atzori et al. CLINICAL CANCER RESEARCH
- Successful Treatment of a Patient with Rheumatoid Arthritis and IgA-Kappa Multiple Myeloma with Tocilizumab
- (2011) Yasushi Matsuyama et al. INTERNAL MEDICINE
- Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
- (2011) P Moreau et al. LEUKEMIA
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Ultra High-Risk Myeloma
- (2011) H. Avet-Loiseau Hematology-American Society of Hematology Education Program
- Racial disparities in incidence and outcome in multiple myeloma: a population-based study
- (2010) A. J. Waxman et al. BLOOD
- A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
- (2010) M. Hussein et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Aptamers as therapeutics
- (2010) Anthony D. Keefe et al. NATURE REVIEWS DRUG DISCOVERY
- An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma
- (2009) Ravi Vij et al. AMERICAN JOURNAL OF HEMATOLOGY
- A monoclonal gammopathy precedes multiple myeloma in most patients
- (2009) B. M. Weiss et al. BLOOD
- Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
- (2009) M. Fulciniti et al. BLOOD
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
- The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells In vitro and In vivo
- (2009) H. Ikeda et al. CLINICAL CANCER RESEARCH
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
- (2009) Shaji K. Kumar et al. MAYO CLINIC PROCEEDINGS
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
- Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy
- (2008) Constantin N. Baxevanis et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70
- (2008) J. A. McEarchern et al. CLINICAL CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Aptamer-modified gold nanoparticles for targeting breast cancer cells through light scattering
- (2008) Yu-Fen Huang et al. JOURNAL OF NANOPARTICLE RESEARCH
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- Role of Antibody Paratope Conformational Flexibility in the Manifestation of Molecular Mimicry
- (2007) Lavanya Krishnan et al. BIOPHYSICAL JOURNAL
- Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu
- (2007) Y.-T. Tai et al. BLOOD
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started